A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : RAGE

Search Conditions:
Search Keyword : RAGE
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: RAGE
Appearance Frequency: 2920 time(s)
Long forms: 71

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
receptor for advanced glycation end products
(2233 times)
Biochemistry
(241 times)
HMGB1 (381 times)
AGEs (179 times)
sRAGE (173 times)
1995 The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.
receptor for AGEs
(539 times)
Biochemistry
(83 times)
AGEs (375 times)
AGE (115 times)
ROS (47 times)
1993 Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro.
AGE receptor
(56 times)
Biochemistry
(10 times)
AGEs (29 times)
AGE (21 times)
NF-kappaB (5 times)
1997 Advanced glycation end products, oxidant stress and vascular lesions.
Rating Scale for Aggressive Behaviour in the Elderly
(7 times)
Geriatrics
(6 times)
MMSE (2 times)
AD (1 time)
BARS (1 time)
1997 Aggressive behaviour in the Chinese elderly--validation of the Chinese version of the rating scale for aggressive behaviour in the elderly (RAGE) in hospital and nursing home settings.
AGEs-their receptor
(4 times)
Medicine
(4 times)
AGEs (4 times)
ROS (1 time)
VEGF (1 time)
2005 Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
rapid amplification of genomic ends
(3 times)
Molecular Biology
(2 times)
PCR (2 times)
gDNA (1 time)
1997 Rapid amplification of gene ends (RAGE) from gene libraries by anchored PCR.
RNAi-Assisted Genome Evolution
(3 times)
Biotechnology
(2 times)
RNAi (1 time)
2014 Genome-wide RNAi screen reveals the E3 SUMO-protein ligase gene SIZ1 as a novel determinant of furfural tolerance in Saccharomyces cerevisiae.
random activation of gene expression
(2 times)
Biotechnology
(1 time)
cDNA (1 time)
EST (1 time)
HTS (1 time)
2001 Creation of genome-wide protein expression libraries using random activation of gene expression.
rapid acquisition gradient-echo
(2 times)
Radiology
(1 time)
IPH (1 time)
MP (1 time)
MR (1 time)
1997 Gadolinium-enhanced breath-hold three-dimensional time-of-flight MR angiography of the abdominal and pelvic vessels: the value of ultrafast MP-RAGE sequences.
10  rapid gradient-echo
(2 times)
Diagnostic Imaging
(2 times)
MP (1 time)
SIR (1 time)
TOF (1 time)
1993 Three-dimensional MR imaging of the coronary arteries: preliminary clinical experience.
11  recent understanding of this process has confirmed that AGEs-their receptor
(2 times)
Medicine
(2 times)
AGEs (2 times)
TAGE (2 times)
AD (1 time)
2005 Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
12  recombinase-assisted genome engineering
(2 times)
Science
(2 times)
BAC (1 time)
2013 Implementation of stable and complex biological systems through recombinase-assisted genome engineering.
13  redox balance, expression of the AGE receptor
(2 times)
Biochemistry
(2 times)
AGEs (2 times)
GLP-1 (1 time)
2010 Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15.
14  reducing receptor for AGEs
(2 times)
Metabolism
(2 times)
AGEs (2 times)
ROS (2 times)
ADMA (1 time)
2012 Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.
15  renal tumor antigen
(2 times)
Neoplasms
(2 times)
HCC (1 time)
MALDI-PSD (1 time)
MMP-9 (1 time)
1998 Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
16  research advanced glycation end-product receptors
(2 times)
Otorhinolaryngologic Diseases
(1 time)
3'-UTR (1 time)
ARE (1 time)
SGC (1 time)
2004 AU-rich elements in the mRNA 3'-untranslated region of the rat receptor for advanced glycation end products and their relevance to mRNA stability.
17  restriction analysis of gene expression
(2 times)
Neoplasms
(1 time)
RT-PCR (1 time)
2003 Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids.
18  roles of AGEs and its receptor
(2 times)
Cell Biology
(2 times)
AGEs (2 times)
DM (1 time)
IL (1 time)
2010 Advanced glycation end products, oxidative stress and diabetic nephropathy.
19  AGE-specific receptor
(1 time)
Rheumatology
(1 time)
AGE (1 time)
IgG (1 time)
OA (1 time)
2005 Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis.
20  anti-AGE receptor
(1 time)
Allergy and Immunology
(1 time)
AGE-HSA (1 time)
AGEs (1 time)
ECs (1 time)
2006 Advanced glycation end products induce actin rearrangement and subsequent hyperpermeability of endothelial cells.
21  Currently, advanced glycation end product
(1 time)
Neoplasms
(1 time)
CI (1 time)
sRAGE (1 time)
WMD (1 time)
2014 Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.
22  down-regulate the mRNA level of the AGE receptor
(1 time)
Biochemistry
(1 time)
AGEs (1 time)
CAT (1 time)
EGCG (1 time)
2007 Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells.
23  radical scavenging; AGE cross-link breaking; AGE receptor
(1 time)
Biology
(1 time)
AGE (1 time)
AGEs (1 time)
2006 Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes.
24  RAGE Ab
(1 time)
Allergy and Immunology
(1 time)
at-HMGB1 (1 time)
DRG (1 time)
ds-HMGB1 (1 time)
2014 Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain.
25  RAGE gene knockout
(1 time)
Cardiology
(1 time)
ALI (1 time)
ARDS (1 time)
IL (1 time)
2018 Role of Receptor for Advanced Glycation End Products in Regulating Lung Fluid Balance in Lipopolysaccharide-induced Acute Lung Injury and Infection-Related Acute Respiratory Distress Syndrome.
26  Rage KO
(1 time)
Endocrinology
(1 time)
AT2 (1 time)
KO (1 time)
2010 Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.
27  RAGE-apt
(1 time)
Natural Science Disciplines
(1 time)
AGE (1 time)
ALDO (1 time)
CML (1 time)
2018 RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice.
28  RAGE-aptamers
(1 time)
Endocrinology
(1 time)
AGEs (1 time)
2017 RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
29  RAGE-v
(1 time)
Biochemistry
(1 time)
--- 2017 Biophysical characterization of Ca2+-binding of S100A5 and Ca2+-induced interaction with RAGE.
30  RAGEDeltacyto
(1 time)
Geriatrics
(1 time)
SCs (1 time)
2011 Human muscle satellite cells show age-related differential expression of S100B protein and RAGE.
31  raised against receptor for AGEs
(1 time)
Endocrinology
(1 time)
ADMA (1 time)
AGEs (1 time)
DDAH (1 time)
2013 Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction.
32  RANKL and receptor for AGE
(1 time)
Endocrinology
(1 time)
OPG (1 time)
RANK (1 time)
RANKL (1 time)
2014 RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy.
33  Rapid analysis of gene expression
(1 time)
Biochemistry
(1 time)
--- 1999 Rapid analysis of gene expression (RAGE) facilitates universal expression profiling.
34  recently, AGE-their receptor
(1 time)
Medicine
(1 time)
AGE (1 time)
AGEs (1 time)
2005 Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
35  Recently, the activation of the advanced glycation endproducts receptor
(1 time)
Vascular Diseases
(1 time)
NFAT (1 time)
siRNA (1 time)
STAT (1 time)
2011 RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.
36  receptor expression for AGEs
(1 time)
Cardiology
(1 time)
AGE-HSA (1 time)
AGEs (1 time)
EMSA (1 time)
2009 Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways.
37  receptor for advanced AGEs
(1 time)
ACS (1 time)
AGEs (1 time)
cTnI (1 time)
2011 Inverse Association between Cardiac Troponin-I and Soluble Receptor for Advanced Glycation End Products in Patients with Non-ST-Segment Elevation Myocardial Infarction.
38  receptor for advanced glycation end products advanced glycation end products
(1 time)
Neoplasms
(1 time)
CRC (1 time)
HMGB1 (1 time)
NF-kappaB (1 time)
2018 Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway.
39  receptor gene for advanced glycation
(1 time)
Gynecology
(1 time)
--- 2010 Implication of the RAGE-EN-RAGE axis in endometriosis.
40  receptor ligation
(1 time)
Nutritional Sciences
(1 time)
AGEs (1 time)
COX-2 (1 time)
MAPK (1 time)
2006 Effects of flavonoids on the expression of the pro-inflammatory response in human monocytes induced by ligation of the receptor for AGEs.
41  receptor of AGE expression
(1 time)
Nephrology
(1 time)
AGEs (1 time)
HPMC (1 time)
PD (1 time)
2002 AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression.
42  Receptor pro konene produkty pokroile glykace
(1 time)
Internal Medicine
(1 time)
AGEs (1 time)
2014 [Receptor pro konene produkty pokroile glykace (RAGE) - kliovy hra diabeticke angiopatie?].
43  receptor protein for AGE
(1 time)
Medicine
(1 time)
AD (1 time)
AGEs (1 time)
sRAGE (1 time)
2012 Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease.
44  receptor was investigated for AGE
(1 time)
Ophthalmology
(1 time)
AGEs (1 time)
CEC (1 time)
2003 Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells.
45  receptors including those of the final glucosiding product
(1 time)
Physiology
(1 time)
--- 2006 [Participation of the DNA-binding cytokine amphoterine in triggering the processes of tissue reparation].
46  receptors placed on neighboring cells
(1 time)
Biochemistry
(1 time)
AGE (1 time)
2011 Transmission of prions within the gut and towards the central nervous system.
47  receptors, including advanced glycation end product-specific receptor
(1 time)
Nephrology
(1 time)
AGEs (1 time)
2016 Uremic Toxicity of Advanced Glycation End Products in CKD.
48  recognized by AGE receptors
(1 time)
Chemistry, Clinical
(1 time)
AGEs (1 time)
NF-kB (1 time)
2006 Glycation endproducts in osteoporosis--is there a pathophysiologic importance?
49  recombination-dependent activatable gene expression
(1 time)
Biochemistry
(1 time)
AR (1 time)
beta-AR (1 time)
EGFP (1 time)
2006 Inducible model for beta-six-mediated site-specific recombination in mammalian cells.
50  reductase pathway and the increased AGE interactions with its receptor
(1 time)
Science
(1 time)
AGEs (1 time)
2005 Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury.
51  regulated by the AGES-receptor
(1 time)
Cell Biology
(1 time)
AGEs (1 time)
VSMC (1 time)
2015 Glycolaldehyde-derived advanced glycation end products (glycol-AGEs)-induced vascular smooth muscle cell dysfunction is regulated by the AGES-receptor (RAGE) axis in endothelium.
52  regulated by the membrane receptors for Abeta1-42 peptides
(1 time)
Pharmacology
(1 time)
--- 2012 Anti-Abeta-MAb and dually decorated nanoliposomes: effect of Abeta1-42 peptides on interaction with hCMEC/D3 cells.
53  related to AGE-receptor for AGE
(1 time)
Nephrology
(1 time)
AGE (1 time)
GDP (1 time)
PDF (1 time)
2006 Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.
54  relatively little AGE-receptor
(1 time)
Nephrology
(1 time)
AGE-HSA (1 time)
1999 The use of optical sensors to understand cellular interactions with renal cells.
55  Removal of alleles by genome editing
(1 time)
Biology
(1 time)
--- 2019 Removal of alleles by genome editing (RAGE) against deleterious load.
56  removal of deleterious alleles by genome editing
(1 time)
Biology
(1 time)
--- 2019 Removal of alleles by genome editing (RAGE) against deleterious load.
57  renal hypertrophy as well as overexpression of AGE receptors
(1 time)
Endocrinology
(1 time)
AGE (1 time)
LZ (1 time)
MS (1 time)
2008 Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy.
58  renaturing agarose gel electrophoresis
(1 time)
Toxicology
(1 time)
AE (1 time)
DDC (1 time)
DPC (1 time)
1998 Differential sensitivity of chromium-mediated DNA interstrand crosslinks and DNA-protein crosslinks to disruption by alkali and EDTA.
59  Research Diagnostics, Flanders, NJ
(1 time)
Brain
(1 time)
AD (1 time)
2008 Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.
60  response is attributed to apically oriented AGE receptors
(1 time)
Ophthalmology
(1 time)
AGE (1 time)
DME (1 time)
RPE (1 time)
2015 Receptor mediated disruption of retinal pigment epithelium function in acute glycated-albumin exposure.
61  responses, AGE receptors
(1 time)
Neurology
(1 time)
LBs (1 time)
MDAL (1 time)
PD (1 time)
2010 Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
62  Rhythmic Analysis of Gene Expression
(1 time)
Medical Informatics
(1 time)
--- 2003 Phase-independent rhythmic analysis of genome-wide expression patterns.
63  robust increase in both myocardial AGE receptor
(1 time)
Cell Biology
(1 time)
AGEs (1 time)
CD (1 time)
2018 Reduced Susceptibility to Sugar-Induced Metabolic Derangements and Impairments of Myocardial Redox Signaling in Mice Chronically Fed with D-Tagatose when Compared to Fructose.
64  role of advanced glycation end products(AGEs) and their receptor
(1 time)
Ophthalmology
(1 time)
AGEs (1 time)
2005 [Molecular mechanism of diabetic retinopathy: role of advanced glycation end products(AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy].
65  role of AGEs and of their specific receptors
(1 time)
Endocrinology
(1 time)
AGEs (1 time)
2001 Advanced glycation end products, their receptors and diabetic angiopathy.
66  roles of high-mobility group box-1, advanced glycation end-products receptors
(1 time)
Pharmacology
(1 time)
--- 2010 Inflammation in ischaemic brain injury: current advances and future perspectives.
67  rotavirus acute gastroenteritis
(1 time)
Allergy and Immunology
(1 time)
RV (1 time)
2013 A reverse evidence of rotavirus vaccines impact.
68  ruling out effects of cellular advanced glycation end product receptor
(1 time)
Dermatology
(1 time)
--- 2002 Photosensitized growth inhibition of cultured human skin cells: mechanism and suppression of oxidative stress from solar irradiation of glycated proteins.
69  superfamily--receptor for advanced glycation endproducts
(1 time)
Therapeutics
(1 time)
FH1 (1 time)
2016 The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease.
70  up-regulation of receptor for AGEs
(1 time)
Pharmacology
(1 time)
AGEs (1 time)
GS (1 time)
IL-6 (1 time)
2015 Polyphenol isolated from Corni Fructus, 7-O-galloyl-D-sedoheptulose, modulates advanced glycation endproduct-related pathway in type 2 diabetic db/db mice.
71  up-regulation of the advanced glycation end product receptors
(1 time)
Cell Biology
(1 time)
HMGB1 (1 time)
2011 Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein.